UCB Reveals New Three-Year Data from Phase 3 Trials of BIMZELX

New Data Announcement: UCB released three-year data from Phase 3 trials and open-label extensions for BIMZELX, focusing on adults with active psoriatic arthritis, non-radiographic axial spondyloarthritis, and ankylosing spondylitis.

Sustained Improvements: The trials showed sustained improvements in disease measures for psoriatic arthritis over three years, including peripheral arthritis, dactylitis, enthesitis, and skin and nail psoriasis.

Clinical Response in Axial Spondyloarthritis: Half of the patients with axial spondyloarthritis maintained a sustained clinical response to stringent endpoints throughout the study period.

Real-World Findings: Initial real-world data indicated rapid improvements in quality of life for patients with psoriatic arthritis, non-radiographic axial spondyloarthritis, and ankylosing spondylitis.